Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.5 EUR | +0.43% | +2.79% | +10.76% |
Apr. 26 | FAES FARMA : Q1 beat; full-year guidance re-affirmed | |
Apr. 15 | Faes Farma, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- This company will be of major interest to investors in search of a high dividend stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- Most analysts recommend that the stock should be sold or reduced.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.76% | 1.17B | B | ||
+33.43% | 690B | C+ | ||
+26.43% | 546B | B | ||
-5.12% | 358B | C+ | ||
+19.59% | 323B | B- | ||
+4.89% | 287B | C+ | ||
+14.32% | 235B | B+ | ||
+5.79% | 199B | B- | ||
-9.49% | 195B | A+ | ||
+4.26% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FAE Stock
- Ratings Faes Farma, S.A.